Barclays
MENS

Barclays’s Jyong Biotech MENS Stock Holding History

Barclays’s Portfolio MENS Stock Details MENS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2K Buy
5,189
+1,649
+47% +$4.03K ﹤0.01% 4680
2025
Q4 		$14K Buy
+3,540
New +$125K ﹤0.01% 4908

Other funds holding MENS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.32B AUM 51.82% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays's MENS Position: Q1 2026 in Review

Barclays increased its Jyong Biotech (MENS) stake by 47% in Q1 2026, buying an estimated $4.03K and bringing the position to 5,189 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4680.

Barclays first reported a position in MENS in Q4 2025 and has held it in 2 quarters since. The position peaked at $14K in Q4 2025. 17 funds tracked by Wall St. Rank hold MENS as of Q1 2026.

  • Barclays held 5,189 shares of Jyong Biotech worth $11.2K as of Q1 2026.
  • Barclays bought 1,649 Jyong Biotech shares in Q1 2026, an estimated $4.03K.
  • Jyong Biotech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4680 holding.
  • Barclays first reported a position in Jyong Biotech in Q4 2025 and has held it in 2 quarters since.
  • Barclays's Jyong Biotech position peaked at $14K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Jyong Biotech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.